Glaukos Co. (NYSE:GKOS) Director Sells $787,062.50 in Stock

Glaukos Co. (NYSE:GKOS) Director Marc Stapley sold 6,250 shares of the business’s stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $125.93, for a total value of $787,062.50. Following the sale, the director now owns 34,076 shares in the company, valued at $4,291,190.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Glaukos Stock Down 0.7 %

Shares of NYSE:GKOS traded down $0.94 during trading on Monday, hitting $126.49. The company’s stock had a trading volume of 403,954 shares, compared to its average volume of 593,276. The company has a market capitalization of $6.37 billion, a PE ratio of -44.07 and a beta of 1.05. Glaukos Co. has a fifty-two week low of $59.22 and a fifty-two week high of $128.51. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.68 and a current ratio of 5.48. The stock’s 50-day moving average price is $118.53 and its two-hundred day moving average price is $105.14.

Glaukos (NYSE:GKOS) last announced its earnings results on Wednesday, July 31st. The medical instruments supplier reported ($0.52) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.52). The company had revenue of $95.70 million for the quarter, compared to analyst estimates of $88.86 million. Glaukos had a negative return on equity of 22.51% and a negative net margin of 47.39%. Glaukos’s quarterly revenue was up 19.0% on a year-over-year basis. During the same period in the prior year, the company posted ($0.55) EPS. As a group, sell-side analysts expect that Glaukos Co. will post -2.25 EPS for the current year.

Analysts Set New Price Targets

GKOS has been the topic of several recent research reports. BTIG Research boosted their price objective on shares of Glaukos from $112.00 to $131.00 and gave the stock a “buy” rating in a research report on Monday, July 15th. JPMorgan Chase & Co. increased their price target on Glaukos from $108.00 to $110.00 and gave the stock an “overweight” rating in a research note on Thursday, May 2nd. Stifel Nicolaus raised their price objective on Glaukos from $110.00 to $130.00 and gave the stock a “buy” rating in a report on Wednesday, June 5th. Morgan Stanley upped their target price on Glaukos from $100.00 to $120.00 and gave the company an “equal weight” rating in a research note on Monday, July 15th. Finally, Needham & Company LLC raised their price target on Glaukos from $131.00 to $137.00 and gave the stock a “buy” rating in a research note on Thursday, August 1st. Four analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, Glaukos presently has an average rating of “Moderate Buy” and a consensus target price of $127.73.

Institutional Investors Weigh In On Glaukos

Institutional investors and hedge funds have recently made changes to their positions in the company. Point72 Asset Management L.P. acquired a new position in Glaukos in the second quarter valued at approximately $67,460,000. Primecap Management Co. CA boosted its position in Glaukos by 43.9% during the 2nd quarter. Primecap Management Co. CA now owns 1,220,815 shares of the medical instruments supplier’s stock valued at $144,483,000 after purchasing an additional 372,180 shares during the period. Norges Bank acquired a new position in Glaukos during the 4th quarter valued at approximately $28,807,000. Allspring Global Investments Holdings LLC grew its stake in Glaukos by 148.3% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 412,376 shares of the medical instruments supplier’s stock worth $48,805,000 after buying an additional 246,322 shares during the last quarter. Finally, Cubist Systematic Strategies LLC acquired a new stake in Glaukos in the fourth quarter worth $15,065,000. 99.04% of the stock is owned by institutional investors and hedge funds.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.